I am a
Home I AM A Search Login

Papers of the Week

Papers: 29 Jan 2022 - 4 Feb 2022

Pharmacology/Drug Development

2022 Jan 27

Br J Dermatol

The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose-response in chronic hand eczema in a 16-week randomised phase 2b trial.


Worm M, Thyssen JP, Schliemann S, Bauer A, Shi VY, Ehst B, Tillmann S, Korn S, Resen K, Agner T
Br J Dermatol. 2022 Jan 27.
PMID: 35084738.


Chronic hand eczema (CHE) is a burdensome disease, and new well-documented, safe, and efficacious treatments are warranted. In a recent CHE phase 2a trial, the pan-Janus kinase (JAK) inhibitor delgocitinib in an ointment formulation was found to be efficacious and well-tolerated.